This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Shire Human Genetic Therapies, Inc., University of Colorado. Active years: 2020.
Company Filing History:
1 out of 86 
1 out of 1,447 
Years Active: 2020
Title: Gregory Seedorf: Innovator in Bronchopulmonary Dysplasia Treatment
Introduction
Gregory Seedorf is a notable inventor based in Aurora, CO (US). He has made significant contributions to the field of medicine, particularly in the treatment of chronic lung disorders. His innovative work focuses on addressing bronchopulmonary dysplasia (BPD), a serious condition affecting premature infants.
Latest Patents
Seedorf holds a patent for "Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia." This invention provides methods and compositions for treating BPD. The patent outlines a method that includes administering an effective amount of an anti-Flt-1 antibody to individuals suffering from or susceptible to BPD. This treatment aims to reduce the intensity, severity, or frequency of symptoms associated with the condition.
Career Highlights
Throughout his career, Gregory Seedorf has worked with prominent organizations, including Shire Human Genetic Therapies, Inc. and the University of Colorado. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of his notable coworkers include Steven Abman and Dennis Keefe. Their collaborative efforts have further advanced the understanding and treatment of bronchopulmonary dysplasia.
Conclusion
Gregory Seedorf's innovative work in developing treatments for bronchopulmonary dysplasia highlights his commitment to improving patient outcomes. His contributions to medical science continue to pave the way for advancements in the treatment of chronic lung disorders.